載入...
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Talimogene laherparepvec is a first-in-class intralesional oncolytic immunotherapy. In a recent Phase III trial (OPTiM), talimogene laherparepvec significantly improved durable response rate compared with subcutaneous granulocyte–macrophage colony-stimulating factor (GM-CSF). Overall response rate w...
Na minha lista:
| 發表在: | Cancer Immunol Immunother |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer Berlin Heidelberg
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5445176/ https://ncbi.nlm.nih.gov/pubmed/28238174 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-017-1967-1 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|